Literature DB >> 11685055

Controlled study of the use of autologous serum in dry eye patients.

N Tananuvat1, M Daniell, L J Sullivan, Q Yi, P McKelvie, D J McCarty, H R Taylor.   

Abstract

PURPOSE: To determine the efficacy and safety of topical autologous serum as a treatment of dry eye patients.
METHODS: A 2-month, prospective, single-masked, placebo-controlled study was conducted in patients with bilateral severe dry eye. One eye was randomized to receive the patient's own serum as a tear substitute, and the fellow eye received unpreserved normal saline solution as a placebo. Subjective symptoms and clinical parameters of dry eye including conjunctival impression cytology were assessed at baseline and 1 week, 1 month, and 2 months after treatment.
RESULTS: Twelve dry eye patients were enrolled. Both subjective symptoms (discomfort, foreign-body sensation, dryness, and photophobia), objective signs (fluorescein and rose bengal staining and conjunctival impression cytology) improved significantly in treated eyes compared with baseline. Control eyes also had improvement in symptoms, signs, and rose bengal staining compared with baseline. Neither Schirmer test results nor tear break-up time improved in either group. The means score of all parameters were improved in both groups, and the results of conjunctival impression cytology were better in treated eyes; however, these results are not significantly different. There were no serious adverse effects observed in this study.
CONCLUSIONS: There was a trend toward improvement in symptoms and signs of dry eye including cytologic changes after application of autologous serum in severe dry eye patients. However, this trend was not statistically significant. A larger scale study is warranted.

Entities:  

Mesh:

Year:  2001        PMID: 11685055     DOI: 10.1097/00003226-200111000-00005

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  39 in total

1.  The treatment of dry eyes.

Authors:  J P Whitcher
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

Review 2.  [Dry eye. An update on epidemiology, diagnosis, therapy and new concepts].

Authors:  F Schirra; K W Ruprecht
Journal:  Ophthalmologe       Date:  2004-01       Impact factor: 1.059

3.  An optimised protocol for the production of autologous serum eyedrops.

Authors:  L Liu; D Hartwig; S Harloff; P Herminghaus; T Wedel; G Geerling
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

Review 4.  [Albumin eye drops for treatment of ocular surface diseases].

Authors:  J D Unterlauft; M Kohlhaas; I Hofbauer; K Kasper; G Geerling
Journal:  Ophthalmologe       Date:  2009-10       Impact factor: 1.059

Review 5.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

Review 6.  Therapeutic Strategies to Treat Dry Eye in an Aging Population.

Authors:  Nisreen S Ezuddin; Karam A Alawa; Anat Galor
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

7.  Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis.

Authors:  Massimo Franchini; Mario Cruciani; Carlo Mengoli; Giuseppe Marano; Enrico Capuzzo; Ilaria Pati; Francesca Masiello; Eva Veropalumbo; Simonetta Pupella; Stefania Vaglio; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-05       Impact factor: 3.443

8.  Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease.

Authors:  Kyung-Sun Na; Man Soo Kim
Journal:  J Ocul Pharmacol Ther       Date:  2012-06-25       Impact factor: 2.671

9.  The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study.

Authors:  Ali Riza Cenk Celebi; Cemalettin Ulusoy; G Ertugrul Mirza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-25       Impact factor: 3.117

Review 10.  Autologous serum eye drops for ocular surface disorders.

Authors:  G Geerling; S Maclennan; D Hartwig
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.